Dr. Lee currently serves as Senior Vice President and Head of Portfolio Strategy at Blueprint Medicines, a publicly traded, global precision therapy company focused on cancer and hematological disorders. Since joining the company in 2014, Dr. Lee has served in positions of increasing responsibility, leading new product strategy, contributing to the IPO, establishing the commercial organization, building infrastructure to enable patient access, and leading multiple new product launches. In her current role, she is responsible for providing strategic and operational leadership across the portfolio, leading the portfolio management team as well as the program leadership and program management functions.

Prior to joining Blueprint Medicines, Dr. Lee served as Head of U.S. Marketing at Algeta ASA, where she was the second hire in the U.S. In this role, she contributed to build the fully integrated organization that successfully launched Xofigo® (radium-223 dichloride), a first in class alpha-emitting radiopharmaceutical. Algeta was acquired by Bayer AG in 2014.

Earlier in her career, she held oncology marketing roles at Sanofi and Genzyme, driving global product launches and a mature product turnaround. As a healthcare strategy consultant at Health Advances, she advised biopharmaceutical and diagnostics clients bringing novel products to market.

Dr. Lee earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology. She conducted post-doctoral research in the lab of Jim Collins at Boston University.